Efficacy and safety of sapropterin before and during pregnancy: Final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) maternal and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU‐MOMs sub‐registries
Authors:
Open Access
- 3 March 2024
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (4) , 636-650
Abstract
Infants born to mothers with phenylketonuria (PKU) may develop congenital abnormalities because of elevated phenylalanine (Phe) levels in the mother during pregnancy. Maintenance of blood Phe levels between 120 and 360 μmol/L reduces risks of birth defects. Sapropterin dihydrochloride helps maintain blood Phe control, but there is limited evidence on its risk–benefit ratio when used during pregnancy. Data from the maternal sub‐registries—KAMPER (NCT01016392) and PKUDOS (NCT00778206; PKU‐MOMs sub‐registry)—were collected to assess the long‐term safety and efficacy of sapropterin in pregnant women in a real‐life setting. Pregnancy and infant outcomes, and the safety of sapropterin were assessed. Final data from 79 pregnancies in 57 women with PKU are reported. Sapropterin dose was fairly constant before and during pregnancy, with blood Phe levels maintained in the recommended target range during the majority (82%) of pregnancies. Most pregnancies were carried to term, and the majority of liveborn infants were reported as ‘normal’ at birth. Few adverse and serious adverse events were considered related to sapropterin, with these occurring in participants with high blood Phe levels. This report represents the largest population of pregnant women with PKU exposed to sapropterin. Results demonstrate that exposure to sapropterin during pregnancy was well‐tolerated and facilitated maintenance of blood Phe levels within the target range, resulting in normal delivery. This critical real‐world data may facilitate physicians and patients to make informed treatment decisions about using sapropterin in pregnant women with PKU and in women of childbearing age with PKU who are responsive to sapropterin.Keywords
Funding Information
- BioMarin Pharmaceutical
- Merck KGaA
This publication has 29 references indexed in Scilit:
- Phenylalanine hydroxylase deficiency treatment and management: A systematic evidence review of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2023
- The role of folate metabolism in orofacial development and cleftingDevelopmental Biology, 2015
- The Kuvan® Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin2015
- Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight casesJournal of Inherited Metabolic Disease, 2014
- The effects of tetrahydrobiopterin (BH4) treatment on brain function in individuals with phenylketonuriaNeuroImage: Clinical, 2013
- Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardationJournal of Inherited Metabolic Disease, 2012
- Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: Results of a phase 3b studyMolecular Genetics and Metabolism, 2011
- Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaAmerican Journal of Medical Genetics Part A, 2008
- The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R‐tetrahydrobiopterin): a phase II, multicentre, open‐label, screening studyJournal of Inherited Metabolic Disease, 2007
- Maternal phenylketonuria collaborative study (MPKUCS) offspring: Facial anomalies, malformations, and early neurological sequelaeAmerican Journal of Medical Genetics, 1997